The recent evidences provided in metastatic hormone sensitive prostate cancer (nmHSPC) and in nonmetastatic castration resistant (nmCRPC) introduced the possibility to adopt Androgen Receptor Signaling inhibitor (ARSi) alone (both settings) or with chemotherapy (in mHSPC). In daily clinical practice there are some opening questions regarding the inclusion of next generation imaging, mainly PSMA-PET, how integrate local treatment as radiotherapy, how to select patients or drugs in a multiple-choice scenario, and how to manage patients with comorbidities and polypharmacy. These issues led the Italian Society for Uro-Oncology (SIUrO) to develop a consensus project involving all of the most important Italian scientific societies engaged in the multidisciplinary and multiprofessional management of the disease. This paper describes the items and statements approved, with the aim to support clinicians in managing metastatic hormone sensitive and nonmetastatic castration resistant prostate cancer patients.
Clinical genitourinary cancer. 2024 Dec 16 [Epub ahead of print]
Rolando Maria D'Angelillo, Orazio Caffo, Nicolò Borsellino, Giampiero Cardone, Giuseppe Ferdinando Colloca, Giario Natale Conti, Marzia Del Re, Stefano Fanti, Barbara Alicja Jereczek-Fossa, Alberto Lapini, Giovanni Luigi Pappagallo, Tommaso Prayer Galetti, Sergio Bracarda
Radiation Oncology, Department of Biomedicine and Prevention University of Rome "Tor Vergata", Rome, Italy. Electronic address: ., Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy., UOC of Medical Oncology, Buccheri La Ferla-Fatebenefratelli Hospital, Palermo, Italy., Radiology Department, IRCCS Ospedale San Raffaele-Turro, Università Vita-Salute San Raffaele, Milan, Italy., Department of Geriatrics, Orthopedics and Rheumatology, Fondazione A Gemelli IRCCS, largo A Gemelli 8, Rome IT Society for Uro-Oncology (SIURO), Bologna, Italy., General Secretary of Italian Society for Uro-Oncology (SIUrO), Rome, Italy., Saint Camillus International University of Medical and Health Sciences, Rome, Italy., Medicina Nucleare, IRCCS AOU di Bologna, Italy., Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; Department of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy., SOC Urology, Azienda USL Toscana centro, Firenze, Italy., IRCCS "Sacro Cuore - Don Calabria", Negrar di Valpolicella, VR, Italy., Urolgy Unit, SS Giovanni e Paolo Hospital, Venice, AULSS 3 Serenissima, Regione Veneto, Venezia, Italy., Medical and Translational Oncology, Department of Oncology, Azienda Ospedaliera Santa Maria, Terni, Italy.